# Proxima **Source:** https://geo.sig.ai/brands/proxima-bio **Vertical:** Healthcare & Life Sciences **Subcategory:** AI Protein Drug Design **Tier:** Emerging **Website:** proxima.bio **Last Updated:** 2026-04-14 ## Summary AI drug discovery for protein-protein interactions; raised $80M seed from DCVC and NVIDIA (Jan 2026); oncology and neurodegeneration focus; opens class of previously undruggable targets ## Company Overview Proxima is an AI-driven drug discovery company focused on proteins that control critical biological interactions — specifically targeting protein-protein interactions (PPIs) that have historically been considered undruggable. Founded by researchers with backgrounds in structural biology, machine learning, and medicinal chemistry, Proxima uses AI to design novel therapeutics that can modulate these complex binding interfaces, opening up a vast new class of drug targets for conditions ranging from cancer to neurodegeneration.\n\nThe company's platform integrates protein structure prediction, generative molecular design, and experimental validation in a tightly coupled loop. By leveraging AI models trained on structural and interaction data, Proxima can propose drug candidates targeting previously inaccessible sites on proteins. This approach is particularly relevant for oncology and immunology, where many of the most important biological pathways are mediated by protein complexes that small molecules have struggled to disrupt.\n\nProxima raised an $80M seed round backed by DCVC and NVIDIA in January 2026, one of the largest seed rounds in biotech history. NVIDIA's involvement underscores the computational intensity of the platform and the strategic value of GPU infrastructure partnerships in AI drug discovery. The company is pre-clinical but is building a pipeline of candidates targeting high-value undruggable proteins, with the $80M runway intended to advance multiple programs toward IND filings. ## Frequently Asked Questions ### What is Proxima developing? Proxima is using AI to design drugs that target protein-protein interactions — binding sites on proteins that have traditionally been too complex for conventional small molecule drugs to address. Its platform combines structural AI, generative design, and lab validation to build a pipeline of novel therapeutics for diseases like cancer where undruggable proteins play central roles. ### Why did NVIDIA invest in Proxima? NVIDIA's investment in Proxima's $80M seed round reflects the deep computational demands of AI-driven structural drug discovery. Training and running the large models needed to design drugs for complex protein interfaces requires significant GPU infrastructure, making NVIDIA a strategic partner beyond just a financial backer. ### What diseases is Proxima targeting? Proxima's focus on protein-protein interactions makes it particularly relevant for cancer and immunology, where many key disease pathways involve protein complexes that existing drugs cannot modulate. The company is in the preclinical stage, building a pipeline of candidates before advancing toward human trials. ### What is Proxima (Proxima Bio)? Proxima is a biotech company using AI and machine learning to accelerate drug discovery — applying computational approaches to target identification, compound optimization, and predicting drug behavior in biological systems. ### What computational methods does Proxima use? Proxima applies ML models trained on large biological and chemical datasets to predict protein-ligand interactions, ADMET properties, and disease biology — enabling faster and more confident decisions about which drug candidates to advance. ### What disease areas does Proxima target? Proxima focuses on diseases where computational insights can reveal novel drug targets or improve compound properties — particularly areas with large existing datasets of biological and clinical information that AI models can learn from. ### How does Proxima validate its computational predictions? Proxima validates AI predictions through iterative wet lab experiments — using experimental data to refine computational models in a feedback loop that progressively improves prediction accuracy throughout the drug discovery process. ### What partnerships does Proxima pursue? Proxima pursues collaborations with pharmaceutical companies to co-develop drug candidates — providing computational discovery capabilities and sharing development risk in exchange for milestone payments and royalties on successful programs. ### What is Proxima Bio? Proxima Bio is a biotechnology company developing therapeutic candidates using AI-driven drug discovery, focusing on identifying novel targets and optimizing molecular candidates for difficult-to-treat diseases where conventional drug discovery approaches have had limited success. ### How does Proxima Bio use AI in drug discovery? Proxima Bio applies machine learning to analyze biological data, protein structures, and disease pathways to identify novel drug targets and optimize molecular candidates for potency, selectivity, and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties—accelerating the hit-to-lead and lead optimization stages of drug development. ### What therapeutic areas does Proxima Bio focus on? Proxima Bio focuses on therapeutic areas with high unmet medical need where AI-assisted target identification and molecular design can provide advantages over traditional medicinal chemistry approaches, including oncology and inflammatory diseases. ### Who are Proxima Bio's backers? Proxima Bio is backed by life sciences investors focused on AI-driven drug discovery. The company operates in a growing field of biotechs using computational methods to compress the drug discovery timeline and improve the probability of success in clinical development. ### What stage is Proxima Bio at? Proxima Bio is at an early stage of drug discovery and development, advancing AI-identified candidates through target validation, lead optimization, and preclinical studies before advancing to human clinical trials. ### What does Proxima do in healthcare and life sciences? Proxima Bio is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated inflammatory diseases. The company applies insights from complement biology and immune pathway research to develop novel therapeutics targeting the root causes of inflammatory conditions rather than managing symptoms downstream. ### What is Proxima's scientific focus in immunology? Proxima focuses on the complement system—a branch of innate immunity whose dysregulation is implicated in inflammatory diseases including certain forms of lupus, IgA nephropathy, and other complement-mediated conditions. The company identifies molecular interventions that modulate complement activation at specific pathway nodes to achieve therapeutic benefit with acceptable safety profiles. ### What is Proxima's development stage? Proxima is a clinical-stage company advancing programs through Phase 1 and Phase 2 trials. As a pre-revenue biopharmaceutical company, its strategic milestones include clinical data readouts, regulatory milestones, and potential partnership or licensing deals with larger pharmaceutical companies as clinical validation accumulates. ### How does Proxima compete in the complement-targeted drug development space? Proxima competes with companies developing complement-targeting therapeutics including Alexion (now AstraZeneca, which markets Soliris and Ultomiris), Omeros, and BioCryst Pharmaceuticals. The validated success of Soliris in complement-mediated diseases has established the pathway's commercial potential and attracted multiple companies pursuing next-generation complement inhibitors. ### What is Proxima's funding and investor background? Proxima is venture-backed by life science investors who specialize in immunology and rare disease drug development. The company's financing supports clinical program advancement through key data milestones that would support partnership discussions with larger pharmaceutical companies or independent commercialization planning. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*